Content

Ozempic can’t help your overweight in big tech: Global ETF diversification ideas for 2024

The start of a new year brings a chance for reflection and re-evaluation. For investors, a chance to rebalance. Franklin Templeton ETFs’ Dina Ting and Marcus Weyerer highlight the pitfalls of overweight exposure to mega tech stocks and where in the world to look for diversification in 2024.

This is premium content

You are not logged in, Sign in or register to request access.
Please note: If you had prior access to this content you may need to sign in again.

Asset Owners

If you are an institutional investor you are eligable for free access to all premium content.

Asset Managers

Asset managers with enhanced profiles are eligable for full access.

Please sign-in using your work email address or:

Franklin Templeton

Ozempic can’t help your overweight in big tech: Global ETF diversification ideas for 2024

This is premium content

Asset Owners

Asset Managers

Franklin Templeton

Related categories